Abstract: An active compound of [(24R)-ergosta-7, 22-diene-3 &bgr;,5 &agr;,6 &bgr;-triol] is obtained from isolated active fractions in fungus Cordyceps sinensis and briefly called F8. Use of the active compound F8 is to improve the clinical symptoms of bronchial hyperresponsiveness and pulmonary injury in OA induced BNR model with enhancing Th1 cytokines suppressing Th2 and iNOS cytokines mRNA expression. This work has important pharmacological implications for the prevention and treatment of bronchial asthma in humans.

Abstract: A method for identifying and isolating the active fractions in fungus Cordyceps sinensis. It covers a findings of the structure of an active compound that is present in the active fractions, an isolation method that can be used to extract the active fractions and a specific active compound, and the use of F8, one specific active compound, that is present in the active fractions thus isolated, to improve the clinical symptoms of bronchial hyperresponsiveness and pulmonary injury in OA induced BNR model with enhancing Th1 cytokines suppressing Th2 and iNOS cytokines mRNA expression. This work has important pharmacological implications for the prevention and treatment of bronchial asthma in humans.

Abstract: A method for identifying and isolating the active fractions in Cordyceps sinensis. It covers a findings of the structure of an active compound that is present in the active fraction, an isolation method that can be used to extract the active fractions and a specific active compound, and the use of "H1-A", one specific active compound that is present in the active fractions thus isolated, to ameliorate the clinical symptoms and renal lesions in laboratory mice with induced IgA nephropathy (Berger's disease). This work has important pharmacological implications for the suppression of activated mesangial cells and IgA nephropathy in humans.